Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
@article{Maini1999InfliximabA, title={Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial}, author={R. Maini and E. Clair and F. Breedveld and D. Furst and for the Attract Study Group}, journal={The Lancet}, year={1999}, volume={354}, pages={1932-1939} }
BACKGROUND
Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate.
METHODS
In an… CONTINUE READING
Topics from this paper
Paper Mentions
2,355 Citations
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
- Medicine
- The New England journal of medicine
- 2000
- 2,993
- PDF
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
- Medicine
- Clinical therapeutics
- 2003
- 261
- PDF
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
- Medicine
- The Lancet
- 2009
- 479
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
- Medicine
- Arthritis and rheumatism
- 2004
- 1,129
- PDF
Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit.
- Medicine
- Annals of the rheumatic diseases
- 2004
- 62
- PDF
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.
- Medicine
- Annals of the rheumatic diseases
- 2003
- 173
- PDF
Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab bef
- Medicine
- Arthritis and rheumatism
- 2009
- 382
Long term safety of infliximab.
- Medicine
- Canadian journal of gastroenterology = Journal canadien de gastroenterologie
- 2000
- 109
- PDF
Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
- Medicine
- Seminars in arthritis and rheumatism
- 2009
- 49
References
SHOWING 1-10 OF 22 REFERENCES
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
- Medicine
- The Lancet
- 1994
- 1,708
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
- Medicine
- Arthritis and rheumatism
- 1998
- 1,648
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
- Medicine
- The New England journal of medicine
- 1999
- 2,077
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
- Medicine
- Arthritis and rheumatism
- 1993
- 870
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group.
- Medicine
- The New England journal of medicine
- 1995
- 483
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
- Medicine
- The New England journal of medicine
- 1997
- 1,589
Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
- Medicine
- The Lancet
- 1994
- 656
The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.
- Medicine
- British journal of rheumatology
- 1995
- 230
- PDF
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
- Medicine
- The New England journal of medicine
- 1996
- 648
Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease
- Medicine
- Immunological reviews
- 1995
- 186